Shionogi
SGIOYNext catalyst
S-337395
Respiratory Syncytial Virus Infections
Get an email about SGIOY's next catalysts
Track Shionogi (SGIOY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 4 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
5 upcoming, 1 past
S-337395 Phase 2 Est. Readout
Primary completion for S-337395 trial (NCT07214571) in Respiratory Syncytial Virus Infections
SourceSivopixant Phase 2 Est. Readout
Primary completion for Sivopixant trial (NCT06776432) in Sleep Apnea
SourceS-488210/S-488211 Phase 2 Est. Readout (DURANCE)
Estimated primary completion for S-488210/S-488211 trial (NCT04106115) in Bladder Cancer. Topline data typically follows completion by weeks to months.
SourceSecutrelvir Phase 3 Est. Readout
Estimated primary completion for Secutrelvir trial (NCT07746544) in COVID-19. Topline data typically follows completion by weeks to months.
SourceS-606001 Phase 2 Est. Readout
Primary completion for S-606001 trial (NCT07123155) in Pompe Disease
SourceMarket Overview
Stock performance and key metrics
Oral Glycopyrrolate Liquid
Cerebral Palsy
CLONICEL (Clonidine HCl sustained release)
Attention Deficit Hyperactivity Disorder
Oseltamivir
Influenza
Dolutegravir
Infection, Human Immunodeficiency Virus I
Cefiderocol
Urinary Tract Infections
Ospemifene
Vaginal Dryness
Meropenem
Healthcare-associated Pneumonia (HCAP)
S-268019-b
SARS-CoV-2
MCI-186
Acute Ischemic Stroke (AIS)
GSK1349572
Infection, Human Immunodeficiency Virus
Pravafen
Combined Hyperlipidemia
Olorofim
Invasive Aspergillosis
MT-1186
Amyotrophic Lateral Sclerosis (ALS)
MCI-186 in open label phase
Amyotrophic Lateral Sclerosis (ALS)
PSD502, contains a mixture of lidocaine and prilocaine
Premature Ejaculation
Duloxetine
Back Pain Lower Back Chronic
Duloxetine hydrochloride
Diabetic Neuropathies
Ospemifene (Dose 1)
Atrophy
Nonhormonal vaginal lubricant
Atrophy
GSK1349572 (dolutegravir)
Infection, Human Immunodeficiency Virus I
Lusutrombopag
Chronic Liver Disease
S-217622
SARS-CoV-2 Infection
Ospemifene (Dose 2)
Atrophy
Best Available Therapy
Healthcare-associated Pneumonia (HCAP)
Naldemedine
Opioid-induced Constipation
Baloxavir Marboxil
Influenza
Secutrelvir
SARS-CoV-2
Abacavir/Lamivudine
Infection, Human Immunodeficiency Virus I
S-707106 Dose C
Type 2 Diabetes Mellitus
S-488210/S-488211
Bladder Cancer
SASS-001
Sleep Apnea
S-606001
Pompe Disease
S-555739 Dose 1
Seasonal Allergic Rhinitis
S-309309
Obesity
S-892216
COVID-19
S-337395
Respiratory Syncytial Virus Infections
S-531011
Solid Tumors
Redasemtide
Acute Ischemic Stroke
S-707106 Dose A
Type 2 Diabetes Mellitus
Sivopixant
Sleep Apnea
S-2367 54 Weeks
Obesity
S-3304
Non Small Cell Lung Cancer
S-777469
Atopic Dermatitis
Velneperit
Obesity
S-600918
Chronic Cough
S-2367 (velneperit)
Obesity
S-2367
Obesity
BPN14770
Jordan's Syndrome
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)
Primary Biliary Cirrhosis
Acetazolamide
Sleep Apnea
Ensitrelvir
Long COVID
efavirenz
Infection, Human Immunodeficiency Virus
GSK1265744
Infection, Human Immunodeficiency Virus
S-555739 Dose 2
Seasonal Allergic Rhinitis
S-2367 60 weeks
Obesity
Cetirizine HCl Dose 1
Seasonal Allergic Rhinitis
S-707106 Dose B
Type 2 Diabetes Mellitus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oral Glycopyrrolate Liquid | Phase 3 | Cerebral Palsy | - | - |
CLONICEL (Clonidine HCl sustained release) | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
Oseltamivir | Phase 3 | Influenza | - | - |
Dolutegravir | Phase 3 | Infection, Human Immunodeficiency Virus I | - | - |
Cefiderocol | Phase 3 | Urinary Tract Infections | - | - |
Ospemifene | Phase 3 | Vaginal Dryness | - | - |
Meropenem | Phase 3 | Healthcare-associated Pneumonia (HCAP) | - | - |
S-268019-b | Phase 3 | SARS-CoV-2 | - | - |
MCI-186 | Phase 3 | Acute Ischemic Stroke (AIS) | - | - |
GSK1349572 | Phase 3 | Infection, Human Immunodeficiency Virus | - | - |
Pravafen | Phase 3 | Combined Hyperlipidemia | - | - |
Olorofim | Phase 3 | Invasive Aspergillosis | - | - |
MT-1186 | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
MCI-186 in open label phase | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
PSD502, contains a mixture of lidocaine and prilocaine | Phase 3 | Premature Ejaculation | - | - |
Duloxetine | Phase 3 | Back Pain Lower Back Chronic | - | - |
Duloxetine hydrochloride | Phase 3 | Diabetic Neuropathies | - | - |
Ospemifene (Dose 1) | Phase 3 | Atrophy | - | - |
Nonhormonal vaginal lubricant | Phase 3 | Atrophy | - | - |
GSK1349572 (dolutegravir) | Phase 3 | Infection, Human Immunodeficiency Virus I | - | - |
Lusutrombopag | Phase 3 | Chronic Liver Disease | - | - |
S-217622 | Phase 3 | SARS-CoV-2 Infection | - | - |
Ospemifene (Dose 2) | Phase 3 | Atrophy | - | - |
Best Available Therapy | Phase 3 | Healthcare-associated Pneumonia (HCAP) | - | - |
Naldemedine | Phase 3 | Opioid-induced Constipation | - | - |
Baloxavir Marboxil | Phase 3 | Influenza | - | - |
Secutrelvir | Phase 3 | SARS-CoV-2 | - | - |
Abacavir/Lamivudine | Phase 3 | Infection, Human Immunodeficiency Virus I | - | - |
S-707106 Dose C | Phase 2 | Type 2 Diabetes Mellitus | - | - |
S-488210/S-488211 | Phase 2 | Bladder Cancer | - | - |
SASS-001 | Phase 2 | Sleep Apnea | - | - |
S-606001 | Phase 2 | Pompe Disease | - | - |
S-555739 Dose 1 | Phase 2 | Seasonal Allergic Rhinitis | - | - |
S-309309 | Phase 2 | Obesity | - | - |
S-892216 | Phase 2 | COVID-19 | - | - |
S-337395 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
S-531011 | Phase 2 | Solid Tumors | - | - |
Redasemtide | Phase 2 | Acute Ischemic Stroke | - | - |
S-707106 Dose A | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Sivopixant | Phase 2 | Sleep Apnea | - | - |
S-2367 54 Weeks | Phase 2 | Obesity | - | - |
S-3304 | Phase 2 | Non Small Cell Lung Cancer | - | - |
S-777469 | Phase 2 | Atopic Dermatitis | - | - |
Velneperit | Phase 2 | Obesity | - | - |
S-600918 | Phase 2 | Chronic Cough | - | - |
S-2367 (velneperit) | Phase 2 | Obesity | - | - |
S-2367 | Phase 2 | Obesity | - | - |
BPN14770 | Phase 2 | Jordan's Syndrome | - | - |
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) | Phase 2 | Primary Biliary Cirrhosis | - | - |
Acetazolamide | Phase 2 | Sleep Apnea | - | - |
Ensitrelvir | Phase 2 | Long COVID | - | - |
efavirenz | Phase 2 | Infection, Human Immunodeficiency Virus | - | - |
GSK1265744 | Phase 2 | Infection, Human Immunodeficiency Virus | - | - |
S-555739 Dose 2 | Phase 2 | Seasonal Allergic Rhinitis | - | - |
S-2367 60 weeks | Phase 2 | Obesity | - | - |
Cetirizine HCl Dose 1 | Phase 2 | Seasonal Allergic Rhinitis | - | - |
S-707106 Dose B | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Shionogi's drug pipeline?→
CatalystAlert tracks 57 drug candidates in Shionogi's (SGIOY) pipeline across Phase 3, Phase 2. Its lead program is Secutrelvir (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Shionogi's next FDA catalyst?→
Shionogi's (SGIOY) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SGIOY biotech catalysts?→
Add SGIOY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Shionogi's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.